Current and future priorities in developing optimal HIV medicines


Since zidovudine monotherapy was approved for AIDS diagnosis in 1987, significant progress has been made in designing antiretroviral drugs that are more effective against HIV infection.

The quality of care changed from less effective and potentially toxic mono- and dual treatments used in the early 1990s to increasingly successful and well tolerated mixed drug regimens, including the introduction of fixed-dose combos (FDCs), and the harmonization of treatment regimens between specific groups. In the last three decades, at least 30 individuals and more than 20 dual and triple combined antiretroviral (ARV) medications were approved for treatment, and one dual combination for prevention of HIV infection, many of which are available as generic formulations.

Initially, the global ARV optimization project centered on increasing global access to key ARV medicines available at the time by lowering prices and simplifying production processes, targeting a significant reduction in HIV death, life survival and avoidance of AIDS growth and the risk of population-level HIV transmission.

With the evolving science of HIV treatment in the last decade, new steps were taken to ensure a transition to new drugs and formulations with better efficacy, lower toxicity, limited contraindications and higher durability against drug resistance, to reduce the need to switch to more complex and expensive regimens and also to reduce the risk of HIV transmission at population level.

Over the last decades, optimizing ARV drugs has dramatically improved both treatment and prevention outcomes of global HIV infection. Continued development of compounds and formulations that enhance the effectiveness, safety and tolerability of HIV drugs will bring further progress in this field.

This review tells about the future scope of the new invention towards the field of HIV /AIDS and their medicinal treatment. People who are interested can send their article towards our journal for publication through this link